“michel-vounatsos” Archives

in
Entry Author Date Location
Biogen to Pay Denali $1B to Partner on Parkinson’s Drug & Other Neuro Meds 08/06/20 San Francisco
Biogen Pushes Finalized Filing for Alzheimer’s Drug to Third Quarter 04/22/20 Boston
Biogen Adds Two More Biosimilars in $100M Deal with Samsung Bioepis 11/06/19 Boston
SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease? 05/02/19 National
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More 04/26/19 National
Biogen, Taking Its Crisis “Seriously,” Keeps Focus on Neuroscience 04/24/19 Boston
Adieu to Adu: Biogen’s Big Alzheimer’s Bet Flops, Shares Routed 03/21/19 Boston
Biogen Pays $1B to Broaden Ionis Pact, Betting More on RNA Drugs 04/20/18 Boston
Biogen, Opening Bottlenecks, Sees Spine Drug Sales, Shares Rise 07/25/17 Boston
With Latest Deal, Biogen Bets $120M on Remedy Pharma Stroke Drug 05/15/17 Boston
Will New Data Open “Bottlenecks” For Biogen’s Pricey Spine Drug? 04/26/17 Boston
“Our Son’s Fate”: Parents Fighting for Kids’ Spine Drug Eye New Data 04/20/17 Boston
Biotech Leaders Sign Letter Condemning Trump’s Travel Ban 02/07/17 National
Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof 02/02/17 Boston
Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths 02/01/17 Boston
Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More 12/23/16 National
Biogen Promotes Vounatsos to CEO, Capping Scangos’s 6-Year Run 12/19/16 Boston
Page 1 of 1